Immunogenicity and protective efficacy of attenuated varicella vaccine and the effectiveness and impact of universal vaccination of a child population;Inmunogenicidad y eficacia protectora de la vacuna de la varicela atenuada y efectividad e impacto de la vacunación universal de la población infantil

Vacunas

Volumn 7, Issue 4, 2006, Pages 168-180

  Salleras, L ^a   Moraga, F ^b   Salleras, M ^c   Dominguez A ^a,d   Prat, A ^a   Campins, M ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^d GENERALITAT DE CATALUNYA   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44149103068     PISSN: 15769887     EISSN: 15788857     Source Type: Journal    
DOI: 10.1016/S1576-9887(06)73205-8     Document Type: Review

References (113)

1. M. Takahashi, and A.A. Gershon Varicella Vaccine S.A. Plotkin, E.A. Mortimer, Vaccines 1994 WB Saunders Philadelphia 387 417
2. M. Takahashi Vaccine development Infect Dis Clin North Am 10 1996 469 488
3. M. Tsolia, A.A. Gershon, S.P. Steinberg, and L. Gelb Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of the skin lesions in transmission of varicella-zoster virus J Pediatr 116 1990 184 189
4. A.A. Gershon Varicella-zoster virus: Prospects for control. Advances in pediatric infectious diseases Mosby Year Book 10 1995 93 124
5. a ed. 2003 Masson Barcelona 311 330
6. F.E. André Summary of clinical studies with the OKA live varicella vaccine produced by Smith Kline-RIT Biken J 27 1984 89 98
7. Product Monograph Varilrix#R. GlaxoSmithKline; 2002.
8. R.W. Ellis Varicella vaccine Vaccine 13 1995 1387 1388
9. Product Monograph Varivax#R III. Merck Frosst Canada; 2003.
10. N. Kraiouchkine, A.R. Shaw, P.M. Keller, and DJ. Distefano Comparison of the complete genome sequences of varicella zoster virus Oka/Merck (Varivax) and Oka/GSK (Varilrix) 43rd Interscience Conference on Antimicrobial Agents and Quemotherapy; 14-17 de septiembre de 2003 American Society for Microbiology Chicago, Washigton abstract 6-1652
11. A.A. Gershon Human immune responses to live attenuated varicella vaccine Rev Infect Dis 13 Suppl 11 1991 S957 S959
12. P.J. Provost, D.L. Krah, and B.J. Kuter, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine Vaccine 9 1991 111 116
13. E.H. Wasmuth, and W.J. Miller Sensitive enzyme-linked immunosorbent assay for antibod to varicella zoster virus using purified VZV glycoprotein antigen J Med Virol 32 1990 189 193
14. B. Watson, C. Boardman, D. Laufer, S. Piercy, N. Tustin, and D. Olaleye, et al. Humoral and cell mediate immune responses in healthy children after one or two doses of varicella vaccine Clin Infect Dis 20 1995 316 319
15. A.A. Gershon, P. LaRussa, I. Hardy, S. Steinberg, and R. Silverstein Varicella vaccine: the American experience J Infect Dis 166 Suppl 1992 S63 S68
16. C.J. White, B.J. Kuter, C.S. Hildebrand, K.L. Isganitis, H. Matthews, and W.J. Miller, et al. Varicella vaccine (Varivax) in healthy children and adolescents. Results from a clinical trial, 1987 to 1989 Pediatrics 87 1991 604 610
17. R.E. Weibel, B.J. Neff, B.J. Kuter, H.A. Guess, C.A. Rothenberger, and A.J. Fitsgerald, et al. Live attenuated varicella vaccine: efficacy trial in healthy children N Engl J Med 310 1984 1409 1415
18. B.J. Kuter, R.E. Weibel, H.A. Guess, H. Mathews, D.M. Morton, and B.J. Neff, et al. Oka/Merk varicella vaccine in healthy children: final report of a 2-year efficacy stydy and 7-year follow up studies Vaccine 9 1991 643 647
19. A.M. Arbeter, S.E. Starr, and S.A. Plotkin Varicella vaccine studies in healthy children and adults Pediatrics 78 Suppl 1986 S748 S756
20. A.M. Arbeter, S.E. Starr, S.R. Preblud, T. Ihara, P.M. Paciorek, and D.S. Miller, et al. Varicella vaccine trials in healthy children: a summary of comparative an follow-up studies Am J Child 138 1984 434 438
21. C.E. Johnson, P.A. Shurin, D. Fattlar, L.P. Rome, and M.L. Kumar Live attenuated varicella vaccine in healthy 12-to 24-month-old children Pediatrics 81 1988 512 518
22. R.E. Weibel, B.J. Kuter, B.J. Neff, L.A. Rothenberger, A.J. Fitzgerald, and K.A. Connor, et al. Live Oka/Merck varicella vaccine in healthy children: further clinical and laboratory assessment JAMA 254 1985 2435 2439
23. C.J. White Clinical trials of varicella vaccine in healthy children Infect Dis Clin North Am 10 1996 595 607
24. F. Meurice, J.L. De Bouver, D. Vandevoorde, S. Woods, and H. Bogaerts Immunogenicity and Safety of a Live Attenuated Varicella Vaccine (OKA/SB Bio) in Healthy Children J Infect Dis 174 Suppl 3 1996 S324 S329
25. M. Just, R. Berger, and D. Luescher Live varicella vaccine in healthy individuals Postgrad Med J 61 Suppl 4 1985 S129 S132
26. F.E. André Summary of clinical studies with the OKA live varicella vaccine produced by Smith Kline-RIT Biken J 27 1984 89 98
27. A. Ramkisoon, H.M. Coovadia, P. Yugnundan, I.E. Haffejer, F. Meurice, and D. Vandervoorde Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months S Afr Med J 85 1995 1295 1298
28. A.Y.S. Tan, C.J. Connett, G.J. Connett, S.C. Quek, and H.K. Yap Use of reformulated OKA Strain varicella vaccine (SKB/OKA) in healthy children Eur J Pediatr 155 1996 706 711
29. T. Varis, and T. Vesikari Efficacy of high-titer attenuated varicella vaccine in healthy young children J Infect Dis 174 Suppl 3 1996 S330 S334
30. Kuter BJ, Ngai a, Patterson CM, Staehle BO, Cho I, Mathews H, et al. Safety, tolerability, and immunogenicity of two regimens of OKA/Merck varicella vaccine (Varivax®) in healthy adolescents and adults.
31. A.M. Arberter Clinical trials of varicella vaccine in healthy adolescents and adults Infect Dis Clin North Am 10 1996 609 615
32. A.A. Gershon, S.P. Steinberg, P. LaRussa, A. Ferrara, M. Hammerschlag, and L. Gelb Immunization of healthy adults with live attenuatd varicella vaccine J Infect Dis 158 1988 132 137
33. P.M. Ndumbe, J.R. Cradock-Watson, S. Mac Queen, H. Dunn, F. Andre, and E.G. Davis, et al. Immunization of healthy adults with live attenuated varicella vaccine J Infect Dis 165 1992 852 858
34. N.C. Barzaga, R.H. Florece, and H.L. Bock Reactogenicity and immunogenicity of a varicella vaccine in Healthy seronegative and seropositive subjects South East Asian J Trop Med Public Health 33 2002 259 267
35. V. Tlesnik, V. Prikazsky, and L. Petvaldsk Protective effect of vaccination against chickenpox Epidemiol Mikrobiol Immunol 49 2000 143 147
36. P. Kusowon, S. Sutra, and P. Kosalaraska Advantage of a two-dose versus one dose varicella vaccine in healthy non-immune teeangers and young adults Southeast Asian J Trop Med Public Health 35 2004 697 701
37. a ed. 2003 Masson Barcelona
38. D.A. Clements, S.P. Moreira, P.M. Coplan, C.L. Bland, and E.B. Walter Postlicensure study of varicella vaccine effectiveness in a day care setting Pediatric Infect Dis J 18 1999 1047 1050
39. M. Vazquez, P.S. La Russa, A.A. Gershon, S.P. Steinberg, K. Freudingman, and E.D. Shapiro The effectiveness of the varicella vaccine in clinical practice N Engl J Med 344 2001 955 960
40. M. Vázquez, P.S. LaRussa, A.A. Gershon, L.M. Niccolai, C.E. Muehlenbein, and S.P. Steinberg, et al. Effectiveness over time of varicella vaccine JAMA 291 2004 851 855
41. J.F. Seward, J.X. Zhang, T.J. Maupin, L. Mascola, and A.O. Jumaan Contagiousness of varicella in vaccinated cases: a household contact study JAMA 292 2004 704 708
42. J.H. Passwell, B. Hemo, Y. Levi, R. Ramon, N. Friedman, and L. Lerner-Geva Use of a computerized database to study the effectiveness of an attenuated varicella vaccine Pediatr Infect Dis J 23 2004 221 226
43. R. Sheffer, D. Segal, S. Rahamani, I. Dalal, Y. Linhart, and M. Stein, et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel Pediatr Infect Dis J 24 2005 434 437
44. H.S. Izurieta, P.M. Strebel, and P.A. Blake Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center JAMA 278 1997 1495 1499
45. K. Galil, E. Fair, N. Mountcastle, P. Britz, and J. Seward Younger age at vaccination may increase risk of varicella vaccine failure J Infect Dis 186 2002 102 105
46. K. Galil, B. Lee, T. Strine, C. Carraher, A.L. Baughman, and M. Eaton, et al. Outbreak of varicella at a day-care center despite vaccination N Engl J Med 347 2002 1909 1915
47. B.D. Tugwell, L.E. Lee, K. Lorber, H. Gillette, E.M. Lorber, and K. Hedberg, et al. Chickenpox outbreak in a highly vaccinated school population Pediatrics 113 2004 455 459
48. U. Buchholz, R. Moolenaar, C. Peterson, and L. Mascola Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics 104 1999 561 563
49. M.S. Dworkin, C.E. Jennings, and J. Roth-Thomas, et al. An outbreak of varicella among children attending preschool and elementary school in Illinois Clin Infect Dis 35 2002 102 104
50. B.R. Lee, S.L. Feaver, C.A. Miller, C.W. Hedberg, and K.R. Ehresmann An elementary school outbreak of varicella attributed to vaccine failure: policy implications J Infec Dis 190 2004 477 483
51. M. Marin, H.Q. Nguyen, J. Keen, A.O. Jumaan, P.M. Mellen, and E.B. Hayes, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003 Pediatrics 115 2005 900 905
52. M.B. Haddad, M.B. Hill, and A.T. Pavia, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003 Pediatrics 115 2005 1488 1493
53. D. Miron, I. Lavi, R. Kitov, and A. Hendler Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage Ped Infect Dis J 24 2005 233 236
54. A.S. Lopez, D. Guris, L. Zimmerman, L. Gladden, T. Moore, and D.T. Haselow, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 117 2006 1070 1077
55. M. Takahashi, T. Otsuka, Y. Okuno, Y. Asano, T. Yazaki, and S. Isomura Live vaccine used to prevent.the spread of varicella in children in hospital Lancet 2 1974 1288 1290
56. Y. Naganuma, S. Osawa, and R. Takahashi Clinical application of a live varicella vaccine (OKA strain) in a hospital Biken J 27 1984 59 61
57. Y. Asano, H. Nakayama, T. Yazaki, S. Ito, S. Isomura, and M. Takahashi Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward Pediatrics 59 1977 8 12
58. Y. Asano, T. Yazaki, T. Miyata, H. Nakayama, and S. Hirose Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection Biken J 18 1975 35 40
59. Y. Asano, S. Iwayama, T. Miyata, T. Yazaki, T. Ozaki, and K. Tsuzuki, et al. Spread of varicella in hospitalized children having no direct contact with an indicator zoster case and its prevention by a live vaccine Biken J 23 1980 157 161
60. N. Katsushima, N. Yazaki, M. Sakamoto, J. Fujiyama, M. Nakagawa, and Y. Okuyama, et al. Application of a live varicella vaccine to hospitalized children and its follow-up study Biken J 25 1982 29 42
61. N. Katsushima, N. Yazaki, and M. Sakamoto Effect and follow-up study on varicella vaccine Biken J 27 1984 51 58
62. M.B. Salzman, and C. Garcia Postexposure varicella vaccination in siblings of children with active varicella Pediatr Infect Dis J 17 1998 256 257
63. B. Watson, J. Seward, A. Yang, P. Witte, J. Lutz, and C. Chan, et al. Postexposure effectiveness of varicella vaccine Pediatrics 105 2000 84 88
64. CDC Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Morb Mort Wkly Rep MMWR 45 1996 1 36 (RR-11)
65. CDC Prevention and control of varicella Morb Mort Wkly Rep MMWR 48 1999 1 6
66. K.F. Seward, B.M. Watson, C.L. Peterson, L. Mascola, J.W. Pelosi, and J.X. Zhang, et al. Varicella disease after the introduction of varicella vaccine in the United States 1995-2000 JAMA 287 2002 606 611
67. J. Quian, C. Romero, P. Dalorso, A. Cerisola, and R. Rüttimann Resultados de la vacunación universal a niños de un año con vacuna de la varicela en Montevideo, Uruguay Arch Ped Urug 74 2003 259 267
68. J.P. Mullooly, J.E. Maher, L. Drew, R. Schuler, and W. Hu Evaluation of the impact of an HMO's varicella vaccination program on incidence of varicella Vaccine 22 2004 1480 1485
69. Centers for Disease Control and Prevention (CDC) Decline in annual incidence of varicella - selected states, 1990-2001 Morb Mort Wkly Rep MMWR 52 2003 884 885
70. J.F. Seward Update on varicella Ped Infect Dis J 20 2001 619 621
71. M. Vazquez Varicella infections and varicella vaccine in the 21st century Pediatr Infect Dis J 23 2004 871 872
72. M.M. Davis, M.S. Patel, and A. Gebremariam Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States Pediatrics 114 2004 786 792
73. F. Zhou, R. Harpaz, A.O. Jumaan, C.A. Winston, and A. Shefer Impact of varicella vaccination on health care utilization JAMA 294 2005 797 802
74. M.M. Davis Varicella vaccine, cost-effectiveness analyses, and vaccination policy JAMA 294 2005 845 846
75. M.A. Staat, J. Meinzen-Derr, T. Welch, N.E. Roberts, L. Jamison, and M.A. Gerber, et al. Varicella-related hospitalization and emergency department visit rates, before and after introduction of varicella vaccine, among white and black children in Hamilton County, Ohio Pediatrics 117 2006 e833 e839
76. H.Q. Nguyen, A.O. Jumaan, and J.F. Seward Decline in mortality due to varicella after implementation of varicella vaccination in the United States N Engl J Med 352 2005 450 458
77. K.G. Chant, E.A. Sullivan, M.A. Burgess, M.J. Ferson, J.M. Forrest, and L.M. Baird, et al. Varicella-zoster virus infection in Australia Aust N Z J Public Health 22 1998 413 418
78. [fe de errores en: Aust N Z J Public Health. 1998;22:630]
79. M.S. Lam, S.K. Chew, D.M. Allen, and E.H. Monterio Fatal varicella infections in Singapore Singapore Med J 34 1993 213 215
80. J.C. Bramley, and I.G. Jones Epidemiology of chickenpox in Scotland: 1981 to 1998 Commun Dis Public Health 3 2000 282 287
81. P.Y. Boelle, and T. Hanslik Varicella in non-immune persons: incidence, hospitalization and mortality rates Epidemiol Infect 129 2002 599 606
82. C.K. Fairley, and E. Miller Varicella-zoster virus epidemiology - a changing scene? J Infect Dis 174 Suppl 3 1996 S314 S319
83. H. Rawson, A. Crampin, and N. Noah Deaths form chickenpox in England and Wales 1995-7: analysis of routine mortality data BMJ 323 2001 1091 1093
84. J. Quian, P. Dall'Orso, C. Romero, A. Cerisola, and A. Protasio Análisis de los resultados de la inmunización universal a los 12 meses de edad con vacuna de la varicela, a través de las consultas externas y las hospitalizaciones en el Centro de Referencia Pediátrico de Uruguay Vacunas 6 2005 77 81
85. J. Quian, C. Romero, A. Cerisola, P. Dalorso, R. Rüttiman, and T. Verstraeten Epidemiology of varicella in Uruguay 4 years since the start of universal mass vaccination 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases ESPID Valencia (Spain). May 18-20 2005 Abstract 110
86. T. Verstraeten, J. Quian, and R. Rüttiman High degree of herd immunity among children of all ages following universal mass vaccination of 12 months old in Uruguay 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases ESPID Valencia (Spain). May 18-20 2005 Abstract 116
87. J. Quian, A. Cerisola, C. Romero, P. Dalorso, A. Delfino, and R. Rüttimann, et al. Neurologic complications in children hospitalized with varicella before and after the start of the universal mass vaccination of children at the age of 1 year 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases ESPID Valencia (Spain). May 18-20 2005 Abstract 399
88. a ed. 2003 Masson Barcelona 311 330
89. M. Brisson, N. Gay, W.J. Edmunds, and N.J. Andrews Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox Vaccine 20 2002 2500 2507
90. L. Salleras, M. Salleras, A. Domínguez, A. Prat, and E. Navas Varicela en el adolescente y adulto. Carga de la enfermedad y potencial de prevención mediante la vacunación Vacunas 6 2005 92 106
91. L. Salleras, and J. De Aristegui Vacunación frente a la varicela: ¿selectiva o universal? Vacunas 2 Supl 1 2001 S1 S4
92. S.A. Plotkin Varicella vaccine Pediatrics 97 1996 251 253
93. S.A. Plotkin Une reáction aux conclusions de la conférence de consensus sur le VZV Virologie 2 1998 494 496
94. F.A. Moraga, and M. Campins Prevención de la varicela. ¿Es suficiente la estrategia vacunal actual? Vacunas 3 2005 73 76
95. F. Moraga, and M. Campins Vacuna de la varicela. Una inmunización del niño y del adulto Enferm Infec Microbiol Clin 18 2000 516 518
96. S. Hambleton, and A.A. Gershon Preventing varicella-zoster disease Clin Microbiol Rev 18 2005 70 80
97. S. Hambleton, and A.A. Gershon The impact of varicella vaccination in the United States Sem Pediatr Infect Dis 16 2005 38 43
98. M.E. Halloran, S.L. Cochi, T.A. Lieu, M. Wharton, and L. Fehrs Theoretical effects of routine varicella immunisation of pre-school children in United States Am J Epidemiol 140 1994 81 104
99. M.E. Halloran Epidemiologic effects of varicella vaccination Infect DisClin North Am 10 1996 631 655
100. L. Salleras, A. Domínguez, J. Vidal, P. Plans, M. Salleras, and J.L. Taberner Seroepidemiology of varicella zoster virus infections in Catalonia (Spain). Rationale for universal vaccination programmes Vaccine 19 2001 183 188
101. S. Thomas, J. Wheeler, and A.J. Hall Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study Lancet 360 2002 678 682
102. A. Gershon, P. LaRussa, S. Steinberg, S.H. Lo, N. Mervish, and P. Meier The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox J Infect Dis 173 1996 450 453
103. M. Brisson, and W.J. Edmunds The cost-effectiveness of varicella vaccination in Canada Vaccine 20 2002 1113 1125
104. S. Feldman, W. Hugues, and C. Daniel Varicella in children with cancer: 77 cases Pediatrics 80 1975 388 397
105. S. Feldman, W.T. Hugues, and H.Y. Kim Herpes zoster in children with cancer Am J Dis Child 126 1973 178 184
106. D. Shepp, P. Dandliker, and J. Meyers Current therapy of varicella zoster virus infection in immunocompromised patients Am J Med 85 Suppl 2A 1988 96 98
107. R. Whitley, M. Hitly, R. Haynes, Y. Bryson, J.D. Connor, and S.J. Soong, et al. Vidarabine therapy of varicella in immunosuppressed patients J Pediatr 101 1982 125 131
108. R. Whitley, S. Soong, R. Dolin, R. Betts, C. Linnemann, C. Alford The NIAID Collaborative Study Group Early vidarabine to control the complications of herpes zoster in immunosuppressed patients N Engl J Med 307 1982 971 975
109. W.K. Yih, D.R. Brooks, S.M. Lett, A.O. Jumaan, Z. Zhang, and K.M. Clements, et al. The incidence of varicella and herpes zoster in Massachussets as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003 BMC Public Health 5 2005 68
110. A.O. Jumaan, O. Yu, L.A. Jackson, K. Bohlke, K. Galil, and J.F. Seward Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002 J Infect Dis 191 2005 1999 2001
111. M.N. Oxman, M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, and L.D. Gelb, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2005 2271 2284
112. A. Arvin Aging, immunity, and the varicella-zoster virus N Engl J Med 352 2005 2266 2267
113. D.H. Gilden Varicella-zoster virus vaccine. Grown-ups need it, too N Engl J Med 352 2005 2344 2346